1D.OMalley,P.Gary,R.Salani,et al.Ohio state university,columbus,oh a phase II evaluation of carboplatin/paclitaxel/bevacizumab in the treatment of advanced-stage endometrial carcinoma:report of toxicity[J].Gynecol Oncolo,2011,120(S1):S33.
3Seiji Isonishi,Michiko Suzuki,Masanori Hirama,et al.Use of docetaxel after paclitaxel hypersensitivity reaction in epithelial ovarian and endometrial cancer clinic[J].Ovari Cance,2009,2(1):44-47.
4Toshiaki Sendo,Yoshinori Itoh,Takeshi Goromaru,et al.Role of substance P in Hypersensitivity reactions induced by paclitaxel an anticancer agent[J].Peptides,2004,25(7):1205-1208.
5Castells MC,Tennant NM,Matulonis UA.Hypersensitivity reactions to chemotherapy:outcomes and safety of rapid desensitization in 413 cases[J].J Allergy Clin Immunol,2008,122(3):574-580.
6Anna M.Feldweg,Chyh-Woei Lee,Ursula A.Matulonis,et al.Rapid desensitization for Hypersensitivity reactions to paclitaxel and docetaxel:a new standard protocol used in 77 successful treatments[J].Gynecolog Oncol,2005,96(3):824-829.
9Wada Y,Otoshi M,Jitsuko A,et al. A phase Ⅱ study of weekly paclitaxel for advanced or recurrent breast cancer[J]. Can To Kagaku Ryoho,2007,34(7) : 1041-1045.
10Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer[J]. Clin Oncol, 1996, 14 (6) : 1858-1867.
4Parlkh B, Khanolkar S, Advani SH, et al.Safety profile of single- dose dexamethasone premedication for paclitaxel [ J ]. Clin Oncol, 1996,14(7) :2189-2190.
5Mattern J, Bǜchler MW, Herr I. Cell cycle arrest by glucocorti- coids may protect normal tissue and solid tumors from cancer therapy[J] .Cancer Biol Ther,2007, 6(9) :1345-1354.
6Machuca C, Mendoza-Milla C, Córdova E, et al. Dexamethasone protection from TNF-alpha-induced cell death in MCF-7 cells re- quires NF-kappaB and is independent from AKT [ J ]. BMC Cell Biol,2006, 7(9) :1186-1198.
7O'Cathail SM, Shaboodien R, Mahmoud S, et al. Intravenous Versus oral dexamethasone premedication in preventing paclitaxel infusion hypersensitivity reactions in gynecological malignancies IJ]. Int J Gyneco Cancer,2013,23(7) : 1318-1325.
8H esketh PJ,Arena F, Patel D,et al. A randomized controlled trial of darbepoetinalfa administered as a fixed or weight- baseddose using a front-loading schedule in patients with anemiawho have nonmyeloidmalignancies [J]. Cancer, 2004, 100(4) :859-68.
